We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · December 22, 2022

Trastuzumab Deruxtecan vs Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer: Updated Results From DESTINY-Breast03

The Lancet


Additional Info

The Lancet
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Lancet 2022 Dec 06;[EPub Ahead of Print], SA Hurvitz, R Hegg, WP Chung, SA Im, W Jacot, V Ganju, JWY Chiu, B Xu, E Hamilton, S Madhusudan, H Iwata, S Altintas, JW Henning, G Curigliano, JM Perez-Garcia, SB Kim, V Petry, CS Huang, W Li, JS Frenel, S Antolin, W Yeo, G Bianchini, S Loi, J Tsurutani, A Egorov, Y Liu, J Cathcart, S Ashfaque, J Cortés

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading